1. pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery 2. severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c 3. creatinine clearance (cockcroft-gault equation) \< 30 ml/min or having hemodialysis/peritoneal dialysis 4. known allergy or hypersensitivity to favipiravir 5. gout or history of gout or hyperuricemia two times the upper limit of normal 6. if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus 7. lactating female 8. asymptomatic covid-19 cases 9. mild covid-19 cases not meeting the inclusion criteria symptoms 10. moderate covid-19 cases not meeting the inclusion criteria symptoms (\*all female patients age 18 - 50 years will be screened for pregnancy by urine test \& any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period \& until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)

1. pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery 2. severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c 3. creatinine clearance (cockcroft-gault equation) \< 30 ml/min or having hemodialysis/peritoneal dialysis 4. known allergy or hypersensitivity to favipiravir 5. gout or history of gout or hyperuricemia two times the upper limit of normal 6. if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus 7. lactating female 8. asymptomatic covid-19 cases 9. mild covid-19 cases not meeting the inclusion criteria symptoms 10. moderate covid-19 cases not meeting the inclusion criteria symptoms (\*all female patients age 18 - 50 years will be screened for pregnancy by urine test \& any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period \& until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)

pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c creatinine clearance (cockcroft-gault equation) < 30 ml/min or having hemodialysis/peritoneal dialysis known allergy or hypersensitivity to favipiravir gout or history of gout or hyperuricemia two times the upper limit of normal if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus lactating female asymptomatic covid-19 cases mild covid-19 cases not meeting the inclusion criteria symptoms moderate covid-19 cases not meeting the inclusion criteria symptoms (*all female patients age 18 - 50 years will be screened for pregnancy by urine test & any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period & until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)

pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c creatinine clearance (cockcroft-gault equation) < 30 ml/min or having hemodialysis/peritoneal dialysis known allergy or hypersensitivity to favipiravir gout or history of gout or hyperuricemia two times the upper limit of normal if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus lactating female asymptomatic covid-19 cases mild covid-19 cases not meeting the inclusion criteria symptoms moderate covid-19 cases not meeting the inclusion criteria symptoms (*all female patients age 18 - 50 years will be screened for pregnancy by urine test & any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period & until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)

1. pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery 2. severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c 3. creatinine clearance (cockcroft-gault equation) < 30 ml/min or having hemodialysis/peritoneal dialysis 4. known allergy or hypersensitivity to favipiravir 5. gout or history of gout or hyperuricemia two times the upper limit of normal 6. if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus 7. lactating female 8. asymptomatic covid-19 cases 9. mild covid-19 cases not meeting the inclusion criteria symptoms 10. moderate covid-19 cases not meeting the inclusion criteria symptoms (*all female patients age 18 - 50 years will be screened for pregnancy by urine test & any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period & until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)

1. pregnant (female of childbearing age with positive urine pregnancy test) or miscarriage or within 2 weeks after delivery 2. severe or critical clinical condition as per nmc clinical guideline for covid19 chronic liver with alt/ast increased 5 times higher than the upper limit of normal or with child pugh c 3. creatinine clearance (cockcroft-gault equation) < 30 ml/min or having hemodialysis/peritoneal dialysis 4. known allergy or hypersensitivity to favipiravir 5. gout or history of gout or hyperuricemia two times the upper limit of normal 6. if using remdesivir, lopinavir-ritonavir, hydroxychloroquine or any other antiviral drug with potential effect against sars-cov-2 virus 7. lactating female 8. asymptomatic covid-19 cases 9. mild covid-19 cases not meeting the inclusion criteria symptoms 10. moderate covid-19 cases not meeting the inclusion criteria symptoms (*all female patients age 18 - 50 years will be screened for pregnancy by urine test & any pregnant patient will be excluded. also, the patient must be consented to take contraception or practice celibacy during the study period & until 7 days after treatment. since the expected wash out period of the study drug favipiravir is 10hrs minimum to 27.5hrs maximum (half life is 2-5.5hrs), it is a safe practice to avoid conception for 1 week after stopping the drug of interest)